These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15949595)

  • 21. ¹⁸F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data.
    Siva S; Deb S; Young RJ; Hicks RJ; Callahan J; Bressel M; Mileshkin L; Rischin D; Bernshaw D; Narayan K
    Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1825-32. PubMed ID: 26173619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of serial F-18 FDG PET/CT scans in assessing treatment response and predicting relapses in patients with symptomatic sarcoidosis.
    Maturu VN; Rayamajhi SJ; Agarwal R; Aggarwal AN; Gupta D; Mittal BR
    Sarcoidosis Vasc Diffuse Lung Dis; 2016 Dec; 33(4):372-380. PubMed ID: 28079849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.
    Weber WA; Petersen V; Schmidt B; Tyndale-Hines L; Link T; Peschel C; Schwaiger M
    J Clin Oncol; 2003 Jul; 21(14):2651-7. PubMed ID: 12860940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer.
    Tanvetyanon T; Eikman EA; Sommers E; Robinson L; Boulware D; Bepler G
    J Clin Oncol; 2008 Oct; 26(28):4610-6. PubMed ID: 18824709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer.
    Mac Manus MP; Hicks RJ; Matthews JP; McKenzie A; Rischin D; Salminen EK; Ball DL
    J Clin Oncol; 2003 Apr; 21(7):1285-92. PubMed ID: 12663716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
    van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy.
    Day FL; Link E; Ngan S; Leong T; Moodie K; Lynch C; Michael M; Winton Ed; Hogg A; Hicks RJ; Heriot A
    Br J Cancer; 2011 Aug; 105(4):498-504. PubMed ID: 21792197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
    Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
    Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Scheiderbauer J; Budach W; Kotzerke J; Bares R
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):54-9. PubMed ID: 16896660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
    Tan AC; Emmett L; Lo S; Liu V; Kapoor R; Carlino MS; Guminski AD; Long GV; Menzies AM
    Ann Oncol; 2018 Oct; 29(10):2115-2120. PubMed ID: 30137228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography as a predictor of response in locally advanced non-small-cell carcinoma of the lung.
    Roy S; Pathy S; Kumar R; Mohanti BK; Raina V; Jaiswal A; Taywade S; Garg K; Thulkar S; Mohan A; Mathur S; Behera D
    Nucl Med Commun; 2016 Feb; 37(2):129-38. PubMed ID: 26544097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: a prospective population-based study.
    De Ruysscher D; van Baardwijk A; Steevens J; Botterweck A; Bosmans G; Reymen B; Wanders R; Borger J; Dingemans AM; Bootsma G; Pitz C; Lunde R; Geraedts W; Oellers M; Dekker A; Lambin P
    Radiother Oncol; 2012 Feb; 102(2):228-33. PubMed ID: 22100659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. False-positive findings on [18F]FDG-PET caused by non-neoplastic cellular elements after neoadjuvant chemoradiotherapy for non-small cell lung cancer.
    Ohtsuka T; Nomori H; Watanabe K; Naruke T; Orikasa H; Yamazaki K; Suemasu K; Uno K
    Jpn J Clin Oncol; 2005 May; 35(5):271-3. PubMed ID: 15883125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of residual metabolic activity after treatment in NSCLC patients.
    Velazquez ER; Aerts HJ; Oberije C; De Ruysscher D; Lambin P
    Acta Oncol; 2010 Oct; 49(7):1033-9. PubMed ID: 20831492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of (18)F-FDG PET on treatment strategy and 3D radiotherapy planning in non-small cell lung cancer: A prospective multicenter study.
    Pommier P; Touboul E; Chabaud S; Dussart S; Le Pechoux C; Giammarile F; Carrie C
    AJR Am J Roentgenol; 2010 Aug; 195(2):350-5. PubMed ID: 20651189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
    Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
    J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interim [
    Sachpekidis C; Kopp-Schneider A; Pan L; Papamichail D; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1932-1943. PubMed ID: 33336264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation.
    Hicks RJ; Mac Manus MP; Matthews JP; Hogg A; Binns D; Rischin D; Ball DL; Peters LJ
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):412-8. PubMed ID: 15380574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.